Dose-dependent effects of selenite (Se⁴⁺) on arsenite (As³⁺)-induced apoptosis and differentiation in acute promyelocytic leukemia cells

S Wang¹, Z Geng*¹, N Shi¹, X Li¹ and Z Wang*¹

To enhance the therapeutic effects and decrease the adverse effects of arsenic on the treatment of acute promyelocytic leukemia, we investigated the co-effects of selenite (Se⁴⁺) and arsenite (As³⁺) on the apoptosis and differentiation of NB4 cells and primary APL cells. A 1.0 μM concentration of Se⁴⁺ prevented the cells from undergoing As³⁺-induced apoptosis by inhibiting As³⁺ uptake, eliminating As³⁺-generated reactive oxygen species, and repressing the mitochondria-mediated intrinsic apoptosis pathway. However, 4.0 μM Se⁴⁺ exerted synergistic effects with As³⁺ on cell apoptosis by promoting As³⁺ uptake, downregulating nuclear factor-κB, and activating caspase-3. In addition to apoptosis, 1.0 and 3.2 μM Se⁴⁺ showed contrasting effects on As³⁺-induced differentiation in NB4 cells and primary APL cells. The 3.2 μM Se⁴⁺ enhanced As³⁺-induced differentiation by promoting the degradation of promyelocytic leukemia protein–retinoic acid receptor-α (PML–RARα) oncoprotein, but 1.0 μM Se⁴⁺ did not have this effect. Based on mechanistic studies, Se⁴⁺, which is similar to As³⁺, might bind directly to Zn²⁺-binding sites of the PML RING domain, thus controlling the fate of PML–RARα oncoprotein.

Cell Death and Disease (2015) 6, e1596; doi:10.1038/cddis.2014.563; published online 15 January 2015

Acute promyelocytic leukemia (APL) is a subtype of human acute myeloid leukemia.¹ The promyelocytic leukemia protein–retinoic acid receptor-α (PML–RARα) fusion protein, which is generated from a specific chromosome translocation t(15;17)(q22;q21), is the key driver of APL leukemogenesis.² Arsenic trioxide (ATO), which has been successfully used in the treatment of APL, induces the catabolism of PML–RARα oncoprotein.³ ATO is one of the primary therapeutic agents for APL, but organ toxicity, especially for the liver and kidney, causes excessive pain for patients.⁴,⁵ Studies on the toxicity of arsenic suggest that ATO metabolism increases its toxicity because of oxidative damage and generation of more toxic metabolites, including monomethylarsonous acid and dimethylarsinous acid.⁶–⁹ Thus, identifying new therapeutics to decrease the adverse effects of ATO is necessary.

ATO induces both apoptosis and differentiation in human APL cells.¹⁰ Apoptosis is an ordered cascade of enzymatic events.¹¹ Studies on the mechanism of ATO-induced apoptosis in APL cells suggest that ATO promotes apoptosis through the mitochondria-mediated intrinsic pathway that is induced by oxidative stress and regulated by Bcl-2 family members.¹⁰,¹²,¹³ ATO can also induce apoptosis by inhibiting the nuclear factor-κB (NF-κB) pathway that regulates the expression of various survival proteins.¹⁴,¹⁵ In addition to apoptosis, ATO can induce the differentiation of APL cells by degrading the PML–RARα fusion protein and activating the retinoic acid signaling pathway.¹⁰,¹⁶ Zhang et al.¹⁶ reported that ATO induced the degradations of PML and PML–RARα oncoprotein by directly binding to PML. PML is a zinc-finger protein with a Cys-rich motif that contains a RING domain. The PML RING domain (PML-R) contains two Zn²⁺-binding sites (ZFs) and requires Zn²⁺ for autonomous folding.¹⁷ The conserved Cys12, Cys29, and Cys32 residues in PML-R-ZF1, and Cys24, Cys40, and Cys43 residues in PML-R-ZF2 are the binding sites for trivalent arsenic.¹⁶

Selenium is an essential nutrient element that shows chemopreventive effect and anticancer potential.¹⁸ Li et al.¹⁹ suggested that high dose (5.0–20 μM) of selenite (Se⁴⁺) could induce the accumulation of reactive oxygen species (ROS) and the apoptosis of NB4 cells. Subsequently, Zuo et al.²⁰ and Guan et al.²¹ confirmed that high concentrations of Se⁴⁺ induced the apoptosis of NB4 cells through an ROS-mediated pathway. However, the accumulation of ROS could induce adverse effects to nontumor tissues by causing oxidative damages.²² For cancer treatment, we attempt to increase the anticancer efficacy while decreasing the adverse effects. Thus far, few studies have investigated the effects of 2.0–4.0 μM Se⁴⁺ on the apoptosis and differentiation of human APL cells. Selenium exerts its biological functions dose-dependently.²² In addition, selenium has chemical properties and metabolic

¹State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing, China.

*Corresponding author: Z Geng or Z Wang, State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing 210093, China. Tel: +86 25 83686082; Fax: +86 25 83317761; E-mail: gengzr@nju.edu.cn or wangzl@nju.edu.cn

Abbreviations: As³⁺, arsenite; Se⁴⁺, selenite; ATO, arsenic trioxide; Se²⁺, divalent selenium; FBS, fetal bovine serum; NF-κB, nuclear factor-κB; ROS, reactive oxygen species; PML, promyelocytic leukemia protein; PML-R, PML RING domain; ZFs, Zn²⁺ binding sites; RARα, retinoic acid receptor-α; APL, acute promyelocytic leukemia; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate; DTNB, 5,5′-dithiobis-(2-nitrobenzoic acid); DCF, 2′,7′-dichlorodihydrofluorescein; IA, iodoacetamide; PI, propidium iodide; HMXO1, heme oxygenase-1; UV–vis, ultraviolet-visible; CD, circular dichroism; Rh, hydrodynamic radius; DLS, dynamic light scattering; MALDI-TOF, matrix-assisted laser desorption ionization-time-of-flight; ICP, inductively coupled plasma; MS, mass spectrometry

Received 15.7.14; revised 19.11.14; accepted 28.11.14; Edited by P Salomoni
fates similar to those of arsenic. In consideration of the typical characteristics of ATO in the treatment of APL, we hypothesized that 2.0–4.0 μM Se⁴⁺ might induce some interesting changes in APL cells, such as differentiation and the degradation of PML–RARα.

Combination therapy is widely used in cancer treatment. The relationship between selenium and arsenic is complex. Selenium and arsenic act as metabolic and toxic antagonists. Combining a low concentration of Se⁴⁺ with ATO might decrease the toxicity and increase the curative potency of ATO in the treatment of APL. Thus, it is of great significance to evaluate the effects of combining selenium with arsenic on the apoptosis and differentiation of human APL cells.

In this study, we found dose-dependent contrasting effects of Se⁴⁺ on arsenite (As³⁺)-induced apoptosis and differentiation in NB4 cells and primary APL cells. A 4.0-μM concentration of Se⁴⁺ enhanced As³⁺-induced apoptosis through downregulation of NF-κB and activation of caspase-3, but 1.0 μM Se⁴⁺ failed to elicit these effects. At 2.0–4.0 μM, Se⁴⁺ induced cell differentiation and synergistically promoted As³⁺-induced cell differentiation. Mechanistic studies suggested that Se⁴⁺ might bind directly to PML-R in the form of divalent selenium (Se²⁺) to promote the degradation of PML–RARα oncoprotein.

**Results**

**Effects of Se⁴⁺ and As³⁺ on the growth of NB4 cells.** After 48 h of treatment, cells viability was determined by the Trypan blue exclusion test. The viability of NB4 cells was 98%, and the viability of primary APL cells was 96%. The effects of As³⁺, Se⁴⁺, or their combination on the growth of NB4 cells and primary APL cells were determined by WST-1 cell proliferation assay (Figure 1). Se⁴⁺ exerted dose-dependent effects on NB4 cell proliferation. Se⁴⁺ at 4.0 μM significantly inhibited the growth of NB4 cells, but 1.0 μM Se⁴⁺ did not have this effect. In addition, 1.0 μM Se³⁺ markedly reduced the inhibitory effects of As³⁺ on NB4 cell growth, whereas 4.0 μM Se⁴⁺ enhanced the cell death induced by As³⁺ (Figure 1a). The viability of primary APL cells (%) in response to As³⁺, Se⁴⁺, or their combination was also investigated. Similarly, 4.0 μM Se⁴⁺ inhibited the proliferation of primary APL cells and enhanced As³⁺-induced cell death (Figure 1b).

**Effects of Se⁴⁺ on As³⁺-induced cell apoptosis.** Concentrations of 1.0 and 4.0 μM Se⁴⁺ were used to investigate the effects of Se⁴⁺ on As³⁺-induced apoptosis in NB4 cells and primary APL cells. After 48 h of treatment, 2.0 μM As³⁺ promoted the apoptosis of NB4 cells (Figure 2a). Compared with control, 1.0 μM Se⁴⁺ decreased the percentage of apoptotic cells from 17.9 to 15.8%, but 4.0 μM Se⁴⁺ increased the percentage from 17.9 to 49.0% (Figure 2a). Similarly, 1.0 μM Se⁴⁺ inhibited As³⁺-induced apoptosis in NB4 cells, but 4.0 μM Se⁴⁺ enhanced apoptosis (Figure 2a). We also investigated the effects of 1.0 and 4.0 μM Se⁴⁺ on the apoptosis of primary APL cells (Figure 2b). The potency of Se⁴⁺ and As³⁺ in inducing primary APL cell apoptosis was low, but the characteristics were similar. At 1.0 μM, Se⁴⁺ inhibited As³⁺-induced apoptosis from 15.9 to 9.0%, whereas 4.0 μM Se⁴⁺ enhanced As³⁺-induced apoptosis from 15.9 to 19.5% (Figure 2b).

**Effects of Se⁴⁺ and As³⁺ on cell cycle distribution.** The cell cycle is a highly regulated event that controls the growth and differentiation of cells. Changes in cell cycle distribution might be associated with the apoptosis and differentiation of NB4 cells. Thus, we analyzed the effects of As³⁺ and Se⁴⁺ on the cell cycle distribution (Figure 3). As³⁺ increased the level of SubG₁ cells and blocked the G1/S transition (Figure 3d). Compared with control, the proportion of SubG₁ cells in 4.0 μM Se⁴⁺-treated cells increased from 11.97 to 76.27%, whereas the proportion in 1.0 μM Se⁴⁺-treated cells was not obviously changed. However, both 1.0 and 4.0 μM Se⁴⁺ significantly inhibited the G1/S transition.
and arrested the cell cycle at the G0/G1 phase (Figures 3a–c).
Similarly, 1.0 μM Se⁴⁺ decreased the proportion of SubG1 cells induced by As³⁺ from 29.04 to 11.26%, but 4.0 μM Se⁴⁺ increased this proportion from 29.04 to 95.06% (Figures 3d–f). Compared with the As³⁺-treated group, low concentrations (1.0 and 4.0 μM) of Se⁴⁺ enhanced the inhibition of As³⁺ in the G1/S transition (Figures 3d–f).

**Effects of Se⁴⁺ on arsenic uptake.** Inductively coupled plasma-mass spectrometry (ICP-MS) was used to detect arsenic in NB4 cells. As shown in Figure 4, 1.0 and 4.0 μM Se⁴⁺ inhibited and promoted the uptake of As³⁺ respectively, and this result can explain the dose-dependent contrasting effects of these concentrations of Se⁴⁺ on As³⁺-induced apoptosis.

---

**Figure 2** Effects of As³⁺ and Se⁴⁺ on cell apoptosis. (a) Cell apoptosis in NB4 cells measured by Annexin V-FITC and PI double staining. (b) Cell apoptosis in primary APL cells. Q₁ and Q₃ respectively represent the proportions of dead cells and living cells, and Q₂ and Q₄ were used to calculate apoptotic cells. Figures show a representative experiment from three independent experiments.
Effects of Se\textsuperscript{4+} and As\textsuperscript{3+} on cellular ROS. Cellular ROS were detected using a fluorescence probe 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) by flow cytometry (Figure 5). Both 1.0 and 4.0 \( \mu \)M Se\textsuperscript{4+} decreased the level of cellular ROS (Figure 5a). However, As\textsuperscript{3+} significantly increased cellular ROS after 36 h of treatment. Adding Se\textsuperscript{4+} eliminated the ROS generated by As\textsuperscript{3+} (Figure 5b). The expression of heme oxygenase-1 (HMOX1), a key oxidative stress response enzyme that is upregulated in the presence of elevated ROS, was analyzed by RT-PCR (Figure 5c). As\textsuperscript{3+} upregulated the expression of HMOX1, but Se\textsuperscript{4+} alone had no significant effect. Furthermore, Se\textsuperscript{4+} inhibited the upregulation of HMOX1 induced by As\textsuperscript{3+} (Figure 5d).

Effects of Se\textsuperscript{4+} and As\textsuperscript{3+} on the expression of apoptotic factors. We analyzed the expression of key apoptotic factors by RT-PCR and western blot (Figure 6). As\textsuperscript{3+} upregulated the Bax pro-apoptotic factor and downregulated the Bcl-2 anti-apoptotic factor at both gene and protein levels (Figures 6a and b). Se\textsuperscript{4+} (1.0 and 4.0 \( \mu \)M) did not obviously regulate the expression of Bcl-2, but it downregulated the expression of Bax. Moreover, Se\textsuperscript{4+} (1.0 and 4.0 \( \mu \)M) showed antagonistic effects with As\textsuperscript{3+} on the regulation of Bax and Bcl-2 (Figures 6c and d). The results suggested that Se\textsuperscript{4+} inhibited the mitochondria-mediated apoptosis.

Effects of Se\textsuperscript{4+} and As\textsuperscript{3+} on cell differentiation. The differentiation of NB4 cells and primary APL cells were investigated by FITC anti-human CD11b antibody (Figure 7). At 2.0–4.0 \( \mu \)M Se\textsuperscript{4+} induced the differentiation of NB4 cells, and the numbers of FITC-CD11b-positive cells were obviously increased (Figures 7a and c). Compared with 4.0 \( \mu \)M As\textsuperscript{3+} alone, 3.2 \( \mu \)M Se\textsuperscript{4+} enhanced the As\textsuperscript{3+}-induced differentiation of NB4 cells (Figures 7b and c). In consideration
of the difference between NB4 cells and primary APL cells, we investigated the effects of Se$^{4+}$ and As$^{3+}$ on the expression of CD11b in primary APL cells (Figures 7d–f). Se$^{4+}$ at 3.2 $\mu$M obviously increased the number of FITC-CD11b-positive cells (Figures 7d–f). Meanwhile, Se$^{4+}$ and As$^{3+}$ synergistically promoted the differentiation of primary APL cells (Figures 7e and f). Considering that the differentiation of NB4 cells and primary APL cells is associated with the degradation of PML–RAR$\alpha$ fusion protein, we analyzed the expression of this oncoprotein by western Blot. After 96 h of treatment, 3.2 $\mu$M Se$^{4+}$ dramatically induced the degradation of PML–RAR$\alpha$ oncoprotein (Figures 7g and h). Se$^{4+}$ at 1.0 $\mu$M inhibited As$^{3+}$-induced degradation of PML–RAR$\alpha$ fusion protein, whereas 3.2 $\mu$M Se$^{4+}$ acted synergistically with As$^{3+}$ (0.4 $\mu$M) to promote the degradation of PML–RAR$\alpha$ oncoprotein (Figures 7g and h).

Interactions between Se$^{4+}$ and PML-R. To investigate whether Se$^{4+}$ promotes the catabolism of PML–RAR$\alpha$ oncoprotein by directly interacting with PML-R, we analyzed the interactions between Se$^{4+}$ and PML-R. The intrinsic ultraviolet–visible (UV–vis) absorption peak of PML-R at 280 nm is primarily caused by Trp47, and the intensity of this peak can indicate perturbation of the microenvironment around Trp47. After incubation with Se$^{4+}$ for 15 min, the intensity of the 280 nm peak was increased. Compared with Zn$^{2+}$ and As$^{3+}$, Se$^{4+}$ increased the intensity at 280 nm more obviously (Figure 8a). The conformational changes of PML-R were also detected by circular dichroism (CD). The conformation of the PML-R zinc-finger domain was disordered. Zn$^{2+}$ induced PML-R folding to a stable structure (Figure 8b). Similarly, Se$^{4+}$ and As$^{3+}$ promoted the folding of PML-R (Figure 8b). Compared with Zn$^{2+}$ and As$^{3+}$, Se$^{4+}$ evidently increased the $\beta$-pleated sheet of PML-R (Figures 8b and c). As evidenced by the hydrodynamic radius ($R_H$) of PML-R analyzed by dynamic light scattering (DLS), PML-R was in an unfolded state. Se$^{4+}$ induced the folding of PML-R, because $R_H$ was decreased from 9.1 to 4.3 nm (Figure 8d). Changes in the maximum emission wavelength and intensity of the synchronous fluorescence spectrum ($\Delta \lambda$ = 60 nm) can reflect the microenvironment around Trp47 for PML-R. Se$^{4+}$ dramatically decreased the synchronous fluorescence intensity of PML-R at 285 nm with an increasing mole ratio, but Zn$^{2+}$ and As$^{3+}$ slightly decreased this fluorescence (Figure 8e). Spectrographic analysis suggested that Se$^{4+}$ and As$^{3+}$ promoted the folding of the PML-R zinc-finger domain. Differently, Se$^{4+}$ affected the conformation of PML-R more remarkably.

Zhang et al. reported that Cys residues in PML-R-ZFs were involved in the binding of As$^{3+}$. To determine the mechanism of Se$^{4+}$ binding, the effects of Se$^{4+}$ on thiol groups of PML-R were analyzed by the method of Ellman. A total of 4.76 (thiol group/mol of protein) thiol groups were detected in PML-R (Figure 8f). Unlike Zn$^{2+}$ and As$^{3+}$, Se$^{4+}$ dramatically eliminated the thiol groups in PML-R, indicating stronger coordination with Cys residues (Figure 8f). Subsequently, the
Cys residues involved in selenium binding were detected by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF)-MS. After being incubated with Zn$^{2+}$, As$^{3+}$, or Se$^{4+}$ and then alkylated with iodoacetamide (IA), PML-R was digested by trypsin for analysis. The peaks corresponding to Cys9 (IA-modified) and Cys12 (IA-modified) were detected (Figure 8g). Compared with PML-R, adding Zn$^{2+}$, As$^{3+}$, or Se$^{4+}$ decreased the intensities of these two peaks (Figures 8g–j).

**Discussion**

The chemical properties and metabolic fates of selenium are similar to those of arsenic. 23 Uniquely, selenium is an essential nutrient element that shows lower genotoxicity, cytotoxicity, and oxidative toxicity.18 As ATO has been successfully used in the treatment of APL, combination therapy has been advocated.34 Arsenic generates ROS and induces oxidative damage that limits its application in the treatment of diseases, including cancers.6,35 However, low concentrations of selenium can eliminate ROS and protect organisms. 18 In consideration of the complicated interaction between selenium and arsenic,23 the co-effects of low doses of Se$^{4+}$ and As$^{3+}$ on the apoptosis and differentiation of APL cells were evaluated.

Bcl-2, Bax, NF-кB, and caspase-3, which play key roles in ATO-induced cell apoptosis,10,14,15 were selected to study the mechanism for the apoptosis of NB4 cells induced by As$^{3+}$ (2.0 μM), Se$^{4+}$ (1.0 and 4.0 μM), or a combination of As$^{3+}$ and Se$^{4+}$. As$^{3+}$ arrested the G1/S transition, increased the cellular ROS, upregulated the Bax pro-apoptotic factor, downregulated the Bcl-2 and NF-кB anti-apoptotic factors, and activated caspase-3. These changes of NB4 cells suggested that As$^{3+}$ induced the apoptosis of NB4 cells by promoting the mitochondria-mediated intrinsic pathway and inhibiting the NF-кB pathway.10,13–15

Concentrations of Se$^{4+}$ greater than 2.0 μM inhibit the growth of NB4 cells. 19 However, when the concentration of selenium increased to a certain extent, it will induce the accumulation of ROS in vivo and lead to adverse effects. 22 In this work, 1.0–4.0 μM Se$^{4+}$ inhibited the generation of cellular ROS, upregulated Bax pro-apoptotic factor, downregulated the Bcl-2 and NF-кB anti-apoptotic factors, and activated caspase-3. These changes of NB4 cells suggested that As$^{3+}$ induced the apoptosis of NB4 cells by promoting the mitochondria-mediated intrinsic pathway and inhibiting the NF-кB pathway. 10,13–15

Concentrations of Se$^{4+}$ greater than 2.0 μM inhibit the growth of NB4 cells. 19 However, when the concentration of selenium increased to a certain extent, it will induce the accumulation of ROS in vivo and lead to adverse effects. 22 In this work, 1.0–4.0 μM Se$^{4+}$ inhibited the generation of cellular ROS, upregulated Bax pro-apoptotic factor, downregulated the Bcl-2 and NF-кB anti-apoptotic factors, and activated caspase-3. These changes of NB4 cells suggested that As$^{3+}$ induced the apoptosis of NB4 cells by promoting the mitochondria-mediated intrinsic pathway and inhibiting the NF-кB pathway. 10,13–15

Concentrations of Se$^{4+}$ greater than 2.0 μM inhibit the growth of NB4 cells. 19 However, when the concentration of selenium increased to a certain extent, it will induce the accumulation of ROS in vivo and lead to adverse effects. 22 In this work, 1.0–4.0 μM Se$^{4+}$ inhibited the generation of cellular ROS, upregulated Bax pro-apoptotic factor, downregulated the Bcl-2 and NF-кB anti-apoptotic factors, and activated caspase-3. These changes of NB4 cells suggested that As$^{3+}$ induced the apoptosis of NB4 cells by promoting the mitochondria-mediated intrinsic pathway and inhibiting the NF-кB pathway. 10,13–15

Concentrations of Se$^{4+}$ greater than 2.0 μM inhibit the growth of NB4 cells. 19 However, when the concentration of selenium increased to a certain extent, it will induce the accumulation of ROS in vivo and lead to adverse effects. 22 In this work, 1.0–4.0 μM Se$^{4+}$ inhibited the generation of cellular ROS, upregulated Bax pro-apoptotic factor, downregulated the Bcl-2 and NF-кB anti-apoptotic factors, and activated caspase-3. These changes of NB4 cells suggested that As$^{3+}$ induced the apoptosis of NB4 cells by promoting the mitochondria-mediated intrinsic pathway and inhibiting the NF-кB pathway. 10,13–15
As\textsuperscript{3+}-generated ROS and inhibiting the regulatory effects of As\textsuperscript{3+} toward the Bax pro-apoptotic factor and the Bcl-2 anti-apoptotic factor. In general, As\textsuperscript{3+}-induced apoptosis was more prone to promotion by 4.0 \mu M Se\textsuperscript{4+} than to inhibition. In addition to apoptosis, 2.0–4.0 \mu M Se\textsuperscript{4+} induced the differentiation of NB4 cells and primary APL cells. The combination of 3.2 \mu M Se\textsuperscript{4+} and 0.4 \mu M As\textsuperscript{3+} enhanced the differentiation of NB4 cells. The PML–RAR\textalpha fusion protein is the key driver of APL leukemogenesis and the target of ATO.\textsuperscript{2} The differentiation of human APL cells induced by ATO is related to the degradation of PML–RAR\textalpha fusion protein.\textsuperscript{16} In consideration of the similarity between arsenic and selenium, we hypothesized that Se\textsuperscript{4+}-induced differentiation of NB4 cells and primary APL cells might be related to the degradation of PML–RAR\textalpha fusion protein. The results of western blot confirmed the hypothesis that Se\textsuperscript{4+} caused the decomposition of PML–RAR\textalpha oncoprotein in both NB4 cells and primary APL cells.

The Cys-rich zinc-finger domain of PML-R is the binding domain of As\textsuperscript{3+}.\textsuperscript{16} Similar to As\textsuperscript{3+}, Se\textsuperscript{4+} was readily bound to thiol groups in vitro.\textsuperscript{36} To investigate whether Se\textsuperscript{4+} directly binds to PML-R, the interactions between Se\textsuperscript{4+} and PML-R were studied. The zinc-finger domain of PML-R contains two PML-R-ZFs.\textsuperscript{17} The spectroscopic data herein showed that Zn\textsuperscript{2+}, As\textsuperscript{3+}, and Se\textsuperscript{4+} induced the folding of PML-R and exposed the residues of Cys24, His26, Cys40, and Cys43 near Trp47 in PML-R-ZF2. Compared with Zn\textsuperscript{2+} and As\textsuperscript{3+}, Se\textsuperscript{4+} induced conformational changes of PML-R evidently and uniquely. In addition, more thiol groups in PML-R were involved in the binding of Se\textsuperscript{4+}. GSSeSG is another selenium substrate for proteins that formed by the reduction of Se\textsuperscript{4+} with glutathione.\textsuperscript{36,37} Shi et al.\textsuperscript{35} reported that Se\textsuperscript{2+} was the
terminal form that bound to Cys-rich proteins. In the binding reaction, one \( \text{Se}^{4+} \) needed four Cys residues. Two Cys residues were oxidized to a Cys–Cys pair in the process of reducing \( \text{Se}^{4+} \), whereas the other two bound to the reduced \( \text{Se}^{2+} \) in the form of RSSeSR. In vitro experiments on the interaction between \( \text{Se}^{4+} \) and PML-R suggested that \( \text{Se}^{4+} \) might be reduced to \( \text{Se}^{2+} \) that then bound PML-R. The large conformational changes of PML-R might be ascribed to the formation of disulfide bonds. Moreover, MALDI-TOF-MS spectra showed that Cys9 and Cys12 at PML-R-ZF1 were involved in the binding reaction. Therefore, \( \text{Se}^{2+} \) might be the form of selenium that promoted the in vivo degradation of PML–RARα fusion protein by directly binding to PML-R-ZFs.

In summary, the mechanism for the effects of \( \text{Se}^{4+} \) on As3+ -induced apoptosis and differentiation in NB4 cells and primary APL cells was postulated. As shown in Figure 9, \( \text{Se}^{4+} \) at low concentrations (1.0 and 4.0 \( \mu \text{M} \)) showed contrasting effects on As3+-induced apoptosis in NB4 cells and primary APL cells. On one hand, \( \text{Se}^{4+} \) (1.0 and 4.0 \( \mu \text{M} \)) inhibited the mitochondria-mediated intrinsic apoptosis by eliminating As3+-generated ROS. On the other hand, \( \text{Se}^{4+} \) (4.0 \( \mu \text{M} \)) promoted As3+-induced apoptosis by facilitating the downregulation of NF-κB and the activation of caspase-3. The effects of \( \text{Se}^{4+} \) on As3+-induced differentiation in NB4 cells and primary APL cells were caused by the degradation of PML–RARα oncprotein. Thus, \( \text{Se}^{4+} \), which is similar to As3+, might directly bind to PML-R in the form of \( \text{Se}^{2+} \) to control the fate of PML–RARα fusion protein. In the meantime, Cys9 and Cys12 in PML-R-ZF1 are involved in the binding reaction.

**Materials and Methods**

**Caution.** Safeguards are required to mitigate the potential risk of arsenic compounds.
Chemicals and antibodies. BSA, NaAsO₂, Na₂SeO₃, and anti-PML rabbit mAb were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-Bcl-2 (50E3) rabbit mAb, anti-Bax (D2E11) rabbit mAb, anti-NF-κB p65 (D14E12) XP rabbit mAb, and anti-Caspase-3 (8G10) rabbit mAb were purchased from Cell Signaling Technology (Boston, MA, USA). FITC anti-human CD11b antibody was obtained from BioLegend (San Diego, CA, USA). Anti-β-Actin mouse mAb was purchased from Beyotime (Nantong, China).

Cell culture and cell viability assay. Human NB4 leukemia cells used in the experiments were purchased from SXBIO Biotech, Shanghai, China; NB4 cells were cultured in RPMI-1640 (KeyGEN Biotech, Nanjing, China) with 10% fetal bovine serum (FBS) at 37 °C under a 5% CO₂ atmosphere. After informed consent, the bone marrow of two primary APL patients was acquired from Drum Tower Hospital (Nanjing, China). Human primary APL cells were separated from the bone marrow by traditional Ficoll-Hypaque density centrifugation. The fresh primary APL cells were cultured in RPMI-1640 (KeyGEN Biotech) with 15% FBS at 37 °C under a 5% CO₂ atmosphere. The viability of NB4 cells and primary APL cells were determined by the Trypan blue exclusion method. After culturing for 24, 48, and 96 h, cells were collected and mixed with equal volume of PBS containing 0.4% Trypan blue dye. Cell viability was calculated as the number of viable cells divided by the total number of cells with the grids on the hemacytometer. The effects of Se⁴⁺ and As³⁺ on cell growth were measured with the WST-1 cell proliferation assay kit according to the manufacturer's protocols (KeyGEN Biotech). The cells were seeded at 4 × 10⁴ cells/ml in a 96-well culture plate and then exposed to various concentrations of As³⁺, Se⁴⁺, or their combination for 48 h. Untreated cells served as controls.

Preparation of PML-R. The gene for PML-R was synthesized from Invitrogen Life Technologies (Carlsbad, CA, USA) and cloned into the Ncol–BarH restriction sites of the pET-28a vector (Novagen, San Diego, CA, USA). The expression plasmid pET-28a-PML-R was confirmed by DNA sequencing.

Figure 9 Mechanism for the effects of Se⁴⁺ (1.0 and 4.0 μM) on As³⁺-induced apoptosis and differentiation in NB4 cells and primary APL cells. Se⁴⁺ promotes the degradation of PML–RARα fusion protein by directly binding to the PML-R-ZFs. The decomposition of PML–RARα oncoprotein contributes to the differentiation of NB4 cells and primary APL cells. On one hand, Se⁴⁺ (4.0 μM) prevents the cells from undergoing As³⁺-induced apoptosis by eliminating ROS, downregulating the Bax pro-apoptotic factor, and upregulating the Bcl-2 anti-apoptotic factor. On the other hand, Se⁴⁺ enhances As³⁺-induced apoptosis by downregulating NF-κB and activating caspase-3.

Table 1 RT-PCR primer sequences

| Name          | Sense                                  | Antisense                                  |
|---------------|----------------------------------------|--------------------------------------------|
| HMOX1         | 5′-CTTGGAGGAGTGTGCGAGGACG-3′            | 5′-GTGAGGCCCATGCGAGAAGA-3′                 |
| Bax           | 5′-TGCGAGGCTGCGGACTGCT-3′              | 5′-AGCCTGAGCGACAGCGCAAAGA-3′              |
| Bcl            | 5′-GGGAGGTGTTGGCGCTCT-3′               | 5′-GGCCAAATCTGAGAGCTCTTC-3′               |
| NF-κB         | 5′-CTGCAGGGCCAGCGCAAGAAGA-3′           | 5′-CGCAGGGCCAGACTACTCA-3′                 |
| Caspase-3     | 5′-GGAGAGGCGGACTGCTGAG-3′              | 5′-AAACCGAGGGTTGGAGTA-3′                  |
| β-Actin       | 5′-GGTACCTGAGCGACTACCT-3′              | 5′-TCTTTGATTGCTGGCGTC-3′                  |

Analysis of apoptotic cells by flow cytometry. NB4 cells and primary APL cells were treated with As³⁺ (2.0, 4.0 μM), Se⁴⁺ (1.0 or 4.0 μM), or their combination for 48 h. After treatment, the cells were collected, washed twice with Ca²⁺/Mg²⁺-free PBS, and stained with Annexin V-FITC and propidium iodide (PI). After double staining, the cells were recorded on a BD LSRL Fortessa flow cytometer (Franklin Lakes, NJ, USA). The percentages of apoptotic cells were calculated by BD FACSDiva software (Franklin Lakes, NJ, USA).

Analysis of cellular ROS and cell cycle by flow cytometry. NB4 cells were treated with As³⁺ (2.0, 4.0 μM), Se⁴⁺ (1.0 or 4.0 μM), or their combination for 36 h. Cellular ROS were assessed with the DCFH-DA fluorescent probe. The levels of cellular 2′,7′-dichlorofluorescein (DCF) were positively correlated with ROS. After treatment, NB4 cells were washed twice with PBS and incubated in RPMI-1640 medium containing 10 μM DCFH-DA at 37 °C for 30 min. The cells were then washed twice to remove excess probes for further analysis. The percentages of DCF-positive cells were analyzed by FlowJo 7.6. The peak distribution was determined by PI staining. After 36 h of treatment, NB4 cells were washed twice with Ca²⁺/Mg²⁺-free PBS and then fixed with 70% ethanol at 4 °C for 18 h. To extract low-molecular-weight DNA from cell nuclei, the fixed NB4 cells were digested in 0.5 mg/ml RNase (Sigma, St. Louis, MO, USA) containing PBS at 37 °C for 30 min. The remaining DNA in cells was stained with 0.05 mg/ml PI and reacted in dark at room temperature for 30 min. The data of cell cycle distribution were analyzed by ModFit LT 3.3 software (Franklin Lakes, NJ, USA). Apoptotic and nonapoptotic cells were counted on the basis of DNA content.

Analysis of FITC-CD11b-positive cells by flow cytometry. The differentiation of NB4 cells and primary APL cells was determined with a FITC anti-human CD11b antibody. After 96 h of treatment, cells were washed twice with PBS and counted. A total of 1 × 10⁶ cells in 100 μl of PBS was incubated with 20 μl FITC anti-human CD11b antibody at 4 °C for 30 min. Excess antibody was washed out by PBS. These data were analyzed by BD FACSDiva software.

Measurement of cellular arsenic concentration. After co-treatments with Se⁴⁺ (1.0 or 4.0 μM) and As³⁺ (1.0, 2.0, or 5.0 μM) for 48 h, NB4 cells were washed twice with PBS, counted, and harvested in 1.0 ml of mixture containing 0.4 μl H₂O₂ and 0.6 μl Tris-HNO₃ (50 mM, pH 7.4) for digestion. Digested samples were filtered through a 0.22 μm pore membrane and diluted with deionized water for analysis. The concentrations of arsenic were determined by ICP-MS (ELAN 9000, Waltham, MA, USA).

RT-PCR analysis. Total RNA was extracted from NB4 cells by RNAiso Plus (Takara, Dalian, China). Isolated total RNA (2 μg) was used to perform the reverse transcription with the PrimeScript RT reagent kit (Takara) according to the manufacturer's protocols. The transcribed cDNA (2 μl) was used for PCR amplification with specific primers for HMOX1, caspase-3, Bax, β-Actin, and NF-κB genes. Thirty cycles were performed under the following conditions: 30 s denaturation at 94 °C, 30 s annealing at 52 °C (β-Actin), 57 °C (HMOX1, Bax, β-Actin, NF-κB, and caspase-3), and 30 s extension at 72 °C. The PCR products were separated on 1% agarose gel containing ethidium bromide. The separated bands were photographed on a Gel Doc XR System (Bio-Rad, Hercules, CA, USA). Primer sequences are shown in Table 1.
Western blot analysis. Total protein in NB4 cells and primary APL cells was extracted by ice-cold RIPA cell lysis buffer (Beyotime). The concentration of proteins was determined by a BCA protein quantification kit (Beyotime). Total protein (30 μg) from each sample was separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto a PVDF membrane (Millipore, Billerica, MA, USA). After blocking in 5% skim milk at room temperature for 1 h, the membrane was sequentially incubated with primary and secondary antibodies. Proteins on the PVDF membrane were visualized using chemiluminescent HRP substrate (Millipore). The intensities of the bands were normalized to that of α-Actin. All the experiments were repeated three or more times.

Spectrographic analysis of the interactions between Se(IV)/As(III)/Zn(II) and PML-R. Zn(II), As(III), and Se(IV) were each incubated with PML-R at room temperature for 15 min before spectrographic analysis. UV–vis spectra of PML-R were recorded on a Perkin Elmer Lambda-35 spectrophotometer (Waltham, MA, USA) equipped with 1.0 cm quartz cell. 27,33 The molar ratios of ion to PML-R were increased from 0 : 1 to 10 : 1.

Statistical analysis. Two-tailed Student’s t-tests were performed for comparisons of two groups. A P value of < 0.05 was considered statistically significant.

Conflict of Interest. The authors declare no conflict of interest.

Acknowledgements. We thank Dr J. Ouyang for experimental assistance of the manuscript. This research was supported by the National Basic Research Program of China (2013CB822102) and the National Natural Science Foundation of China (21201101, 21275072, and 21475059).

Se(IV) degrades the PML-RARα oncoprotein

S Wang et al.

Author contributions. Shuping Wang and Dr Zhiling Wang designed research and wrote the paper; Shuping Wang, Nan Shi, Xiaoli Li, and Dr Zhonggen Geng performed experiments and analyzed data.

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505–2515.

2. De Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The [15:17] translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel translocated locus. Nature 1990; 347: 550–551.

3. Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncoribonucleodegradation in disease remission. Oncogene 2001; 20: 7257–7265.

4. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J 2003; 79: 391–396.

5. Legler E, Hoffmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012; 26: 433–442.

6. Tapio S, Grosse B. Arsenic in the arthology of cancer. Mutat Res Rev 2006; 612: 215–246.

7. Cullen WR. Chemical mechanism of arsenic biomethylation. Chem Rev Toxicol 2014; 27: 2157–2195.

8. Thomas DJ, Styblo M, Lin S. The cellular mechanism and systemic toxicity of arsenic. Toxicol Appl Pharm 2001; 176: 127–144.

9. Sharma VK, Sohn M. Aquatic arsenic: toxicity, speciation, transformations, and remediation. Environ Int 2009; 35: 743–759.

10. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262–270.

11. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495–516.

12. Hecht SS, Tchouwou P, Jenkins J, McMurray R. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 2010; 3: 28.

13. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Science 1999; 13: 1899–1911.

14. Mathas S, Lietz A, Junge J, Hummel M, Schindler C et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028–1034.

15. Lemarie A, Morzadec C, Merino D, Micheau O, Fardel O, Vernhet L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. J Pharmacol Exp Ther 2006; 318: 304–314.

16. Zhang SW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328: 240–243.

17. Borden KL, Boddy MN, Lally J, O’Reilly NJ, Martin S, Howe K et al. The solution structure of the RING finger domain from the acute promyelocytic leukemia proto-oncoprotein PML. EMBO J 1995; 14: 1532–1541.

18. Patrick L. Selenium biochemistry and cancer: a review of the literature. Annu Rev Med 2004; 9: 239–258.

19. Li J, Zuo L, Shen T, Xu CM, Zhang ZN. Induction of apoptosis by sodium selenite in human acute promyelocytic leukemia NB4 cells: involvement of oxidative stress and mitochondria. J Trace Elem Med Biol 2003; 17: 19–26.

20. Zuo L, Li J, Yang Y, Wang X, Shen T, Xu CM et al. Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide. Am Hematol 2004; 83: 751–758.

21. Guan JY, Han BS, Li L, Hu PY, Huang F, Wei W et al. Sodium selenite induces apoptosis by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in human acute promyelocytic leukemia NB4 cells. Apoptosis 2009; 14: 218–225.

22. Brenneisen P, Steinbrenner H, Sies H. Selenium, oxidative stress, and health aspects. Mol Aspects Med 2005; 26: 256–266.

23. Zeng H, Ulthus ED, Combs GF. Mechanistic aspects of the interaction between selenium and arsenic. J Inorg Biochem 2005; 99: 1269–1274.

24. Darzyynkiewicz Z, Zhao H, Halicka HD, Rybak P, Dobrucki J, Wiodkowski D. DNA damage signaling assessed in individual cells in relation to the cell cycle phase and induction of apoptosis. Crit Rev Clin Lab Sci 2011; 49: 199–217.

25. Jakoby M, Schnittger A. Cell cycle and differentiation. Curr Opin Plant Biol 2004; 7: 661–669.

26. Watanabe T, Otta Y, Mizumura A, Kobayashi Y, Hirano S. Analysis of arsenic metabolites in HepG2 and ASMT-transfected cells. Arch Toxicol 2011; 85: 577–588.

27. Wang SP, Xu XL, Song XL, Geng ZR, Hu X, Wang ZL. Rapid equilibrium kinetic analysis of dynamic light scattering analysis. The effects of Zn(II), As(III), or Se(IV) on free thiol groups was calculated by the dynamic light scattering software. 32

28. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010; 594: 57–72.

29. Morse D, Choi AMK. Heme oxygenase-1: from bench to bedside. Crit Rev Clin Lab Sci 2005; 42: 660–670.

30. Huerta-Olvera SG, Macías-Barragán J, Ramos-Márquez ME, Armendáriz-Borunda J, Diaz-Barriga F, Siller-López F, Alpha-lipoic acid regulates heme oxygenase gene expression and nuclear Nrf2 activation as a mechanism of protection against arsenic exposure in HepG2 cells. Environ Toxicol Pharmacol 2010; 29: 144–149.
31. Song XL, Geng ZR, Li CY, Hu X, Wang ZL. Transition metal ions and selenite modulate the methylation of arsenite by the recombinant human arsenic (+3 oxidation state) methyltransferase (hAS3MT). J Inorg Biochem 2010; 104: 541–550.
32. Yu Z, Reid JC, Yang YP. Utilizing dynamic light scattering as a process analytical technology for protein folding and aggregation monitoring in vaccine manufacturing. J Pharm Sci 2013; 102: 4284–4290.
33. Bi S, Song D, Tian Y, Zhou X, Liu Z, Zhang H. Molecular spectroscopic study on the interaction of tetracyclines with serum albumins. Spectrochim Acta A Mol Biomol Spectrosc 2005; 61: 629–636.
34. Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011; 117: 6425–6437.
35. Shi HL, Shi XL, Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 2004; 255: 97–78.
36. Patteson KG, Trivedi N, Stadtman TC. Methanococcus vannielii selenium-binding protein (SeBP): chemical reactivity of recombinant SeBP produced in Escherichia coli. Proc Natl Acad Sci USA 2005; 102: 12029–12034.
37. Ogasawara Y, Lacourciere G, Stadtman TC. Formation of a selenium-substituted rhodanese by reaction with selenite and glutathione: possible role of a protein perselenide in a selenium delivery system. Proc Natl Acad Sci USA 2001; 98: 9494–9498.
38. Jiang GS, Bi KH, Tang TH, Zhang YK, Ren HQ, Jiang FQ et al. Effects of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells. Chin Med J 2003; 116: 1639–1643.
39. Wang SP, Shi N, Geng ZR, Li XL, Hu X, Wang ZL. Inhibitory mechanism of dimercapropropylsulfonic acid (DMPS) in the cellular biomethylation of arsenic. Biochimie 2014; 106: 167–174.
40. Geng ZR, Song XL, Xing Z, Geng JL, Zhang SC, Zhang XR et al. Effects of selenium on the structure and function of recombinant human S-adenosyl-L-methionine dependent arsenic (+3 oxidation state) methyltransferase in E. coli. J Biol Inorg Chem 2009; 14: 485–496.
41. Wang SP, Geng ZR, Shi N, Li XL, Hu X, Wang ZL. The functions of crucial cysteine residues in the arsenite methylation catalyzed by recombinant human arsenic (III) methyltransferase. PLoS One 2014; 9: e110924.